CN108066170A - Dermatologic preparation composition containing ginsenoside Mc - Google Patents
Dermatologic preparation composition containing ginsenoside Mc Download PDFInfo
- Publication number
- CN108066170A CN108066170A CN201711172456.6A CN201711172456A CN108066170A CN 108066170 A CN108066170 A CN 108066170A CN 201711172456 A CN201711172456 A CN 201711172456A CN 108066170 A CN108066170 A CN 108066170A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- skin
- composition
- dosage form
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Birds (AREA)
- Pulmonology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of compositions for containing ginsenoside Mc as active ingredient, the composition can not only provide anti-aging, improvement wrinkle of skin, whitening, moisturizing improvement, but also it is capable of providing anti-inflammatory, improvement acne and skin problem, and effect, convergence skin and the pore refining effect of allergic symptom, and be capable of providing skin color improvement, promote hair growth, improve white hair, anti-dandruff and anti-corrosion effect.
Description
The application is Application No. 201480029499.7, the applying date to be on April 24th, 2014, entitled " contain
The divisional application of the Chinese patent application of the Dermatologic preparation composition of ginsenoside Mc ".This application claims April 24 in 2013
The priority for the 10-2013-0045117 korean patent applications that day submits in Korean Intellectual Property Office.
Technical field
The present invention relates to a kind of composition, the composition contains ginsenoside Mc (ginsenoside Mc), so as to not
Only be capable of providing it is anti-aging, improve wrinkle of skin, whitening, moisturizing improvement, but also be capable of providing it is anti-inflammatory, improve acne and
The effect of skin problem and allergic symptom, convergence skin and pore refining effect, and it is capable of providing skin color improvement effect
Fruit promotes hair growth, improves white hair, anti-dandruff and anti-corrosion effect.
Background technology
First defensive barrier of the skin as human body, have so that intracorporeal organ from temperature and humidity variation and it is ultraviolet
The stimulations of external environments such as line, public hazards substance and protect the function of intracorporeal organ.With advancing age, skin will be due to a variety of
Inherent, external factor and change.That is, in terms of the inherence, since the various hormone secretions for adjusting metabolism are reduced,
And the function and cytoactive of immunocyte reduce, therefore the biology of the immune protein of needed by human body and organism constitutive protein
Synthesis is reduced.For in terms of external, due to the destruction of ozone layer, the ultraviolet light content that earth's surface is reached from sunray increases
Add, and as the in-depth of environmental pollution, free radical and active oxygen increase, the thickness reduction of skin, wrinkle is not only caused to increase,
Elastic force reduces, and makes skin complexion dimmed, and problem (trouble) often occurs for skin, can also increase mole and freckle and old age
Spot, and cause the various changes such as complexion is deteriorated, the colour of skin is dimmed.
In order to prevent these due in skin and external factor and occur skin condition variation, and maintain health skin
Skin state, people make great efforts always by the way that the physiological activator obtained from existing various animals, plant, microorganism etc. is added
Enforcement of going forward side by side is added in cosmetics to be used for improving skin condition.
Ginsenoside Mc be the natural goods form contained in ginseng ginsenoside (Rb1, Rg1, Rd, Rb2, Rc, Rf) by
What digestive ferment and intestinal microbial were decomposed and generated.It has been reported that the active anticancer of ginsenoside Mc is strong and Korean granted is special
The method for using ginsenoside Mc as anticancer preparation is recorded in profit the 164266th, but without reporting ginsenoside
Mc is as such as whole skin condition improvement of the composition of active ingredient, promotion hair growth and improves white hair, anti-head
The overall effect as skin preparations for extenal use such as scurf and anti-corrosion.
The content of the invention
Technical problems to be solved
In this regard, the inventors discovered that the ginsenoside Mc contained in ginseng can not only provide anti-aging, improvement skin wrinkle
Line, whitening and moisturizing improvement, but also effect that is anti-inflammatory, improving acne, skin problem and allergic symptom is capable of providing, and
Skin color improvement is capable of providing, promotes hair growth, improve white hair, anti-dandruff and anti-corrosion effect, so as to complete
The present invention.
Therefore, it is an object of the present invention to provide a kind of Dermatologic preparation composition, the composition contains ginsenoside
Mc, so as to show that the integrality of skin improves and promote hair growth, improvement white hair, anti-dandruff and anti-corrosion effect
Fruit.
Technical solution
To achieve these goals, present invention offer is a kind of contains ginsenoside Mc as active ingredient for anti-aging
Dermatologic preparation composition.
In addition, the present invention provides a kind of external preparation for skin for being used to improve wrinkle for containing ginsenoside Mc as active ingredient
Agent composition.
In addition, the present invention provides a kind of skin preparations for extenal use group for moisturizing for containing ginsenoside Mc as active ingredient
Close object.
In addition, the present invention provides a kind of external preparation for skin for being used to improve acne for containing ginsenoside Mc as active ingredient
Agent composition.
In addition, the present invention provides a kind of skin for being used to improve color and the colour of skin for containing ginsenoside Mc as active ingredient
Skin preparation composition for external use.
In addition, the present invention provides a kind of external preparation for skin for pore refining for containing ginsenoside Mc as active ingredient
Agent composition.
In addition, the present invention provides a kind of skin for being used to improve allergic skin for containing ginsenoside Mc as active ingredient
Skin preparation composition for external use.
In addition, the present invention provides a kind of ginsenoside Mc that contains is used for anti-inflammatory skin preparations for extenal use group as active ingredient
Close object.
In addition, the present invention provides a kind of skin preparations for extenal use group for whitening for containing ginsenoside Mc as active ingredient
Close object.
In addition, the present invention provides a kind of ginsenoside Mc that contains is used for trichogenous skin as active ingredient
Preparation composition for external use.
In addition, the present invention provides a kind of external preparation for skin for being used to prevent white hair for containing ginsenoside Mc as active ingredient
Agent composition.
In addition, the present invention provides a kind of external preparation for skin for anti-dandruff for containing ginsenoside Mc as active ingredient
Agent composition.
In addition, the present invention provides a kind of natural antiseptic agent composition by ginsenoside Mc.
Advantageous effect
The composition of the present invention contains ginsenoside Mc, so as to provide anti-aging, improvement wrinkle of skin, U.S.
In vain, moisturizing improvement, but also it is capable of providing anti-inflammatory, improvement acne and the effect of skin problem and allergic symptom, convergence
Skin and pore refining effect, and be capable of providing skin color improvement, promote hair growth, improve white hair, anti-dandruff
And anti-corrosion effect.
Specific embodiment
Dermatologic preparation composition according to the present invention contains ginsenoside Mc as active ingredient.
The ginsenoside Mc used in the present invention has the structure of following chemical formula 1:
[chemical formula 1]
The ginsenoside Mc of the present invention can be extracted from plant, can also be synthesized simultaneously by method as known in the art
It uses, the ginsenoside Mc of mercantile-type sale can also be used.In addition, ginsenoside Mc can be obtained from ginseng extract.
At this moment the species of the ginseng used is not particularly limited, and can use water ginseng, red ginseng, white ginseng, Tai Ji ginseng and tail ginseng etc..Also,
The ginseng extract not only comprising extracted as ginseng, decoct carry obtained from leachate, also include to the part or whole of leachate
Concentrate obtained from body is concentrated again or impregnating, decoction, the tablet dried the concentrate again and preparedFlowing extracts and the chemical substance that main efficacy results are played included in ginseng, but also include plant sheet
Body, and the extract of the entire parts of ginsengs such as stem, root, leaf, flower and fruit can be used, it is not limited to a certain specific part
Extract.In addition, the method for ginsenoside Mc is extracted from ginseng extract can use well known method.
Specifically, the ginsenoside Mc can be made by method as known in the art using water or organic solvent
After standby ginseng extract, therefrom it is isolated.The organic solvent used in the present invention can be selected from ethyl alcohol, methanol, butanol,
Ether, ethyl acetate, chloroform and the mixed solvent of these organic solvents and water, it is preferable to use 80% ethyl alcohol.At this moment, Extracting temperature
Preferably 10~80 DEG C, and can extract 3~24 it is small when.If beyond the Extracting temperature and the scope of extraction time,
Extraction efficiency can reduce or can occur the variation of ingredient.
Composition according to the present invention in terms of composition total weight, preferably comprises the ginsenoside of 0.001 to 50 weight %
Mc.If this is because the content of the ginsenoside Mc is less than 0.001 weight %, the effect of being brought by the ingredient and effect
Fruit is faint, if it exceeds 50 weight %, then can there are problems that in cutaneous safety or dosage form.
The composition of the present invention can be used as and be used for anti-aging Dermatologic preparation composition, in raising skin
Effect in terms of elastic force and improvement wrinkle protrudes.
The composition of the present invention can be used as the Dermatologic preparation composition for moisturizing, can strengthen skin
Barrier function, and it is capable of the differentiation of induced skin keratinocyte.Therefore, can effectively serve as preventing or improving because of epidermis
Not xerodermia, allergic dermatitis, the skin preparations for extenal use for contacting atopic dermatitis or psoriasis etc. completely caused by differentiation
Composition.
The composition of the present invention can be used as improving the Dermatologic preparation composition of acne, antibacterial effect
It is excellent, it is especially excellent to the antibacterial effect of acne pathogenic bacteria, and antiphlogistic effects are provided.
The composition of the present invention can be used as improving the Dermatologic preparation composition of color and the colour of skin, by it
When being used in skin, by expanding capillary, and promote blood circulation that nutritional ingredient smoothly is fed to skin, and inhibit
Skin aging, therefore, the effect for improving color and the colour of skin are remarkable.
The composition of the present invention can be as pore refining, adjusting sebum and the skin preparations for extenal use for improving skin problem
Composition uses, and when being used in skin, inhibits the sebum of excessive secretion, and passes through the elimination for promoting active oxygen and collagen
The synthesis of albumen carrys out pore refining, and due to the reduction of inflammatory Cytokines Expression, the effect for inhibiting skin problem is remarkable.
The composition of the present invention can be used as improving the composition of allergic skin, not only pass through inhibition
Induce the work of the protein decomposition enzyme active acceptor -2 (Proteinase-Activated Receptor-2, PAR-2) of itch
Property, so as to provide excellent antipruritic effect, but also can be by reducing the secretion of interleukin (Interleukin-8, IL8)
To provide anti-inflammatory effect.Therefore, the ginsenoside Mc of the invention can be used as stabilized susceptibility, irritation or mistake
Quick property skin and scalp, and it is appropriate for improving or alleviating the active ingredient of the Dermatologic preparation composition of thermal sensation and inflammation
Ground uses.
The composition of the present invention can be used as the composition for whitening, by the work for hindering tyrosinase
Property, inhibit the generation of melanin, so as to provide excellent whitening effect.
The composition of the present invention can be used as and be used for trichogenous Dermatologic preparation composition, promote
From hair cycle stand-down to the conversion in anagen hair cycle, so as to provide the growth including promoting hair, and promote new
The generation of hair, and make the effect of existing hair health growth also provides and prevents and inhibit hair to show from what scalp came off
As or hair is scattered or the effect of state that attenuates.
The composition of the present invention can be used as preventing the Dermatologic preparation composition of white hair, pass through raising
The expression of transcription factor (MITF) in melanocyte carrys out activation of melanocyte, and promotes the synthesis of melanin, so as to provide
The induction of advance preventing white hair, and promote to induce the effect of dark hair.
The composition of the present invention can be used as preventing the Dermatologic preparation composition of dandruff, by having
Effect discharge is accumulated in the toxin on hair and scalp to purify scalp, and by inhibiting multiplication and the growth of dandruff bacterium and can
Prevent scalp inflammation reaction, also, since the anti-oxidation efficacy of generation and the effect of inhibitory activity oxygen protrudes, therefore, it is possible to carry
For calming and strengthening scalp, and strengthen the effect of intrinsic phylactic power defensive power.
The composition of the present invention can be used as natural antiseptic agent composition, since it is natural component, anti-corrosion
It is also harmless while effect brilliance.
The composition of the present invention can the agent containing acceptable carrier or base material on cosmeceutical or Dermatology
Type.It can be provided as the whole dosage forms for being suitble to locally use, for example, can be provided as solution, gel, solid, paste
The anhydrous product of shape In water phase disperse oil phase and obtain lotion, suspension, microemulsion,
Microcapsules, subparticle ball or ionic (liposome) and non-ionic folliculus dispersant form or frost, toner, wash
Agent, powder, ointment, spray or the form for hiding flaw stick.And it is possible in the form of foam (foam) or further include pushing away for compression
Form into the aerosol combination of agent uses.These compositions can be prepared according to method commonly used in the art.
In particular, the Dermatologic preparation composition of the present invention is used to prevent dandruff, is for hair growth or white for preventing
During hair, can as the composition for scalp and hair and dosage form, dosage form are not particularly limited, such as can be turned to dosage form
Hair oil, trichotrophy toner, scalp care agent, hair-care agent, shampoo, hair conditioner, hair lotion or hair of scalp
Dual-purpose care agent etc..
In addition, composition according to the present invention can include fatty material, organic solvent, lytic agent, concentrating agents, gelling
Agent, softening agent, antioxidant, suspending agent, stabilizer, foaming agent (foaming agent), aromatic, surfactant, water,
Ionic or nonionic emulsifier, filler, chelating agent, complexing agent, preservative agent, vitamin, blocking agent, wetting agent, essential oil,
Dyestuff, pigment, hydrophily or lipophile activating agent, lipid folliculus or any other ingredient for being usually used in cosmetics etc. are in cosmetics
Common adjuvant in or Dermatology field.The adjuvant is with usually used in cosmeceutical or Dermatology field
Amount import.
In addition, the composition of the present invention, in order to increase skin improvement effects, can contain skin absorption enhancement substance.
Embodiment
Hereinafter, the structure and effect of the present invention will be further illustrated by test example and dosage form example.However, these are tested
Example and dosage form example are only to assist in the present invention is understood as purpose is illustrated come what is provided, and scope of the invention and scope are not
It is defined in following examples.
The preparation of [reference example 1] ginsenoside Mc
In order to which the ginsenoside Mc that the effect of present composition is tested and used is studied purchased from peace rich (AMBO)
Institute.
[test example 1] elastase activity inhibits the measure of effect
Ability is hindered for the elastase activity of ginsenoside Mc, with Epigallo-catechin gallate (EGCG)
(EGCG) it is compared and measures.The elastoser and matrix used is commercially public purchased from U.S.'s Sigma-Aldrich
Take charge of the elastoser of (Cat.No.E0127).
Elastase activity inhibition is tested with following test methods.
In 96 orifice plates, 10mg/L Tri(Hydroxymethyl) Amino Methane Hydrochlorides (Tris-HCL) buffer solution is being modulated into
(pH8.0) in, 20 μ g/mL elastoser-type III solution of the ginsenoside Mc and 50 μ L of 200 μ L are mixed.By 250 μM
EGCG is used as positive controls, and the non-process group as negative control group has used distilled water.Afterwards, add
N- succinyl-alanine-the Ala-Alas-of the 0.4514mg/mL modulated with the buffer solution of 100 μ L are to nitro acyl
Aniline (N-SUCCINYL-ALA-ALA-ALA-p-NITROANILIDE), and reacted 15 minutes at 25 DEG C.Reaction terminates
Afterwards, absorbance (synergistic effect 2, the microplate reader (BioTek) (VT, the U.S.) under 415nm wavelength are measured.With identical method come real
It applies blank test and is corrected.
The computational methods of elastase activity inhibition the results are shown in table 1 below as shown in following mathematical expressions 1
In.
Mathematical expression 1
Elastase activity obstruction rate (%)=1- (C-D)/(A-B) × 100
A:In no addition substances, and when adding enzyme, the absorbance under 415nm wavelength
B:In no addition substances, enzyme, the absorbance under 415nm wavelength
C:When adding substances, enzyme, the absorbance under 415nm wavelength
D:Addition substances, without add enzyme when, the absorbance under 415nm wavelength
Table 1
Compound | Inhibition level (%) |
Non-process group | 0 |
EGCG | 65 |
Ginsenoside Mc | 75 |
As shown in above-mentioned table 1, inhibition levels of the ginsenoside Mc to elastase activity is shown, than being known as bullet
Property proteinase activity inhibitor EGCG it is significantly excellent, thus it is confirmed that the present invention ginsenoside Mc elastin laminin enzyme activity
Property inhibition is excellent.
[test example 2] clostridiopetidase A (MMP-1) hinders ability
Obstruction ability is generated for the clostridiopetidase A of the ginsenoside Mc of the present invention, is measured compared with retinoic acid.
Equipped with DMEM (Dulbecco ' s Modified Eagle ' s Media) trainings containing 2.5% fetal bovine serum
In the 96 hole plate incubators (96-well microtiter plate) for supporting base, added in the amount of 5,000 cells/wells (well)
Human fibroblasts, and in 5%CO2, culture is carried out in 37 DEG C of incubators until 70~80% degree are grown to.With 10 μ g/
The ginsenoside Mc of ml concentration or during small retinoic acid treatments 24 after, take cell culture fluid.
Using available commercially as clostridiopetidase A sensing equipment (Amersham Phamarcia companies of the U.S., Catalog#:
RPN2610), the clostridiopetidase A generation degree for the cell culture fluid taken is measured.First, once clostridiopetidase A antibody is smeared uniform
96- hole plates (96-well plate) in add in the cell culture fluid taken, and it is anti-to implement in thermostat Ag-Ab
Answer 3 it is small when.3 it is small when after, the secondary collagen antibody for being combined with colour developing group is added in 96- hole plates, and secondary response again
15 minutes.After 15 minutes, add in as develop the color evocating substance 3,3 ', 5,5 '-tetramethyl benzidine (3,3 ', 5,5 '-
Tetramethylbenzidine, Sigma), and colour developing 15 minutes is induced at room temperature, it adds in 1M sulfuric acid again and stops showing
Colour response, then the color of reaction solution is in yellow, and according to the carry out degree of reaction, the degree of the yellow shown is different.
Using absorptiometer, measure is in the absorbance of the 96- hole plates of yellow under 405nm, and according to following mathematical expressions 2
The synthesis degree of clostridiopetidase A is calculated, and the results are shown in table 2 below.At this moment, by the group of never useful compositions-treated
In the reaction absorbance of cell culture fluid taken as a control group.
Mathematical expression 2
Absorbance × 100 of absorbance/control group of collagenase expression degree (%)=substance processing groups of cells
Table 2
Compound | Expression degree (%) |
Non-process group | 100 |
Retinoic acid | 75 |
Ginsenoside Mc | 73 |
As shown in above-mentioned table 2, it is known that the collagenase expression degree of ginsenoside Mc is with being known as collagenase expression
The retinoic acid of inhibitor is compared, and collagenase expression hinders effect level similar.
By the above results, it can confirm that the ginsenoside Mc of the present invention has and hinder matrix metalloproteinase (MMP-1)
Effect.
[dosage form example 1 and compare dosage form example 1]
According to the composition of Table 3 below, nourishing cream (unit is prepared by conventional method:Weight %).
Table 3
[test example 3] skin elasticity improves effect confirmation
In order to confirm the effect to the raising of the skin elasticity of people, using the dosage form example 1 and the dosage form for comparing dosage form example 1,
And following evaluation is made.
For the healthy women of 20 30 to 40 years old age brackets, it is divided into two groups with every group 10, by dosage form example 1 and compares agent
After the nourishing cream of 1 two groups of type example is applied to face 12 weeks with frequency 1 time a day, skin elasticity tester is utilized
(Cutometer SEM575, C+K Electronics Co., Ltd.s (C+K Electronic Co.), Germany) measures skin elasticity.It is tied
Fruit is represented in table 4 below.The end value of table 4 is remembered with the Δ R8 values of Cutometer (Cutometer SEM 575)
It carries, wherein R8 values represent the property of skin viscoplasticity (viscoelasticity).
Table 4
Experimental products | Skin elasticity effect |
Dosage form example 1 | 0.44 |
Compare dosage form example 1 | 0.10 |
As shown in above-mentioned table 4, the dosage form example 1 of the ginsenoside Mc containing the present invention, the group of dosage form example 1 compared with smearing
It compares, skin elasticity improves more.
Therefore, it can confirm that the composition of the ginsenoside Mc containing the present invention is highly effective to skin elasticity raising.
[test example 4] improves the confirmation of wrinkle of skin effect
In order to confirm that the composition of the present invention to the effect improving wrinkles of people, make use of the dosage form example 1 and compare dosage form
Example 1.
For the effect improving wrinkles for confirming the dosage form example 1 He comparing dosage form example 1, following evaluation has been made.For 20
The healthy women of 40 years old age bracket of name, is divided into two groups with every group 10, by dosage form example 1 and compares the nutrition of 1 two groups of dosage form example
After frost is applied to face 12 weeks with frequency 1 time a day, replica (replica) is taken out using silicon, and uses skinanalysis apparatus
(visiometer, SV600, Courage+Khazaka electronic GmbH, Germany) measures the state of wrinkle, and carries out
Graphical analysis.Its result is represented in table 5 below.The result of table 5 below is represented in each parameter (parameter) after smearing 12 weeks
Subtract the average value after the parameter value before smearing.
Table 5
As shown in above-mentioned table 5, it is known that the preparation composition for external use of dosage form example 1 is to improving the effect of wrinkle of skin very
It is excellent.
[test example 5] tyrosinase hinders effect
Tyrosinase is the extraction from mushroom class (Mushroom), has used the tyrosinase of Sigma.First,
It will be dissolved in as the tyrosine of matrix in distilled water and the solution of 0.3mg/ml be made, and by the solution with every pipe 1.0ml
Amount be added in test tube after, wherein add 1.0ml potassium-phosphate buffer solution (0.1mol concentration, pH6.8) and
The distilled water of 0.7ml.
Sample liquid is prepared to mix ginsenoside Mc with 10ppm in the ethanol solution of the present invention, by the above-mentioned of 0.2ml
Sample liquid is added in reaction solution, is then reacted 10 minutes in 37 DEG C of thermostats.At this moment, 0.2ml solvents will only be added in and carrys out generation
For adding in the group of each sample liquid as a control group, and used using ascorbic acid as positive controls.In the reaction solution
The tyrosinase solution of 2500 units/ml of 0.1ml is separately added into, and is reacted 10 minutes in 37 DEG C of thermostats again.It will dress
The test tube for having the reaction solution, which is put into ice water, makes its rapid cooling, so as to stop reacting, and with photoelectricity spectrum analysis instrument, measures
Absorbance (synergy 2, microplate reader (VT, the U.S.), and the results are shown in table 6 below under 475nm wavelength.Under
It states mathematical expression 3 and hinders effect to calculate each tyrosinase.
Mathematical expression 3
Tyrosinase obstruction rate (%)=100- (the reaction absorbance of reaction absorbance/control group of substances ×
100)
Table 6
Substances | Tyrosinase obstruction rate (%) |
Control group (does not add) | 0 |
Ascorbic acid | 52 |
Ginsenoside Mc | 63 |
It is recognised that ginsenoside Mc according to the present invention is to the inhibiting rate ratio of tyrosinase from the result of above-mentioned table 6
Ascorbic acid as well known tyrosinase inhibitor is much higher, therefore whitening effect is very excellent.
[test example 6] generates inhibition using the melanin of B16/F10 melanoma cells
To the sample of ginsenoside Mc and kojic acid be contained as substances using the amount of 0.001 weight % respectively, and with one
Determine concentration to be added in the culture solution of B16/F10 melanoma cells (bank of Korea Cell system), and cultivate 3 days after, removal training
Then nutrient solution is cleaned with phosphate buffer (PBS), and with after 1N NaOH dissolving cells, absorbance (association is measured under 405nm
With effect 2, microplate reader (VT, the U.S.).To be not added with the cells of substances as a control group, and with the melanin in control group
Content is compared, and measures the degree that each substances hinder melanin generation.Melanin generation suppression is calculated according to mathematical expression 4
Rate processed, and the results are shown in table 7.
Mathematical expression 4
Melanin generating suppression (%)=100- (absorbance × 100 of absorbance/control group of substances)
Table 7
Substances | Melanin generating suppression (%) |
Control group (does not add) | 0 |
Kojic acid | 53 |
Ginsenoside Mc | 66 |
It is recognised that the inhibiting rate that ginsenoside Mc according to the present invention generates melanin from the result of above-mentioned table 7
It is more much higher than the kojic acid as well known melanin generation Inhibitors, therefore whitening effect is very excellent.
[test example 7] skin moisture-keeping power increases effect measuring
The effect generated is increased to skin moisture-keeping power in order to measure ginsenoside Mc, the dosage form example 1 is make use of and compares
Dosage form example 1, and made following evaluation.
For the adult men and women for being categorized as dry skin of 20 40 to 50 years old age brackets, it is divided into two groups with every group 10,
Dosage form example 1 and the nourishing cream for comparing 1 two groups of dosage form example are applied to face 4 weeks with frequency 2 times a day.Smearing start before,
After smearing 1 week, after 2 weeks, after 4 weeks when and stopping smearing by after 2 weeks (altogether by 6 weeks), in constant temperature, constant humidity condition
Under (24 DEG C, relative humidity 40%), moisture of skin tester (Corneometer CM825, C+K Electronics Co., Ltd. (C+ is used
K Electronic Co.), Germany) measure moisture of skin amount.Its result is represented in table 8 below.Table 8 the result is that with experiment
Start the value of the moisture of skin tester measured before as benchmark, by the increase part of the measured value after processing a period of time
Result expressed as a percentage.
Table 8
From the result of the table 8 it has been confirmed that when smearing compares dosage form example 1, until 4 weeks by smearing, show
About 30% moisture increment rate is shown, but stops moisture of skin amount after smearing and reduces, on the contrary, smearing the agent containing ginsenoside Mc
During type example 1, also major part shows more than 30% moisture of skin increment rate after stopping smearing.It is possible thereby to know containing ginseng
The skin moisture-keeping power excellent effect of the composition of the present invention of saponin(e Mc.
[test example 8] Keratinocyte differentiation facilitation effect measures
It is as follows, in order to understand ginsenoside Mc Human Keratinocytes differentiation facilitation effect, using absorbance come
Measure hornification coating (Cornified Envelope, the CE) amount generated during Keratinocyte differentiation.
First, the keratinocyte of the people cultivated after being separated from the epidermis of baby and once is put into culture and burns
In bottle, after it is made to be attached to bottom, with after the ginsenoside Mc processing of the concentration of 5ppm in culture solution, culture 5 days until
Until cell grows to the 70~80% of bottom area.At this point, low calcium (0.03mM) processing group and high calcium (1.2mM) are handled into component
It Zuo Wei not negative control group and positive controls.Then the cell of above-mentioned culture is obtained, after being washed with phosphate buffered saline (PBS),
Add in the Soviet Union of two sulphur containing 2% lauryl sodium sulfate (sodium dodecyl sulfate, SDS) and 20mM concentration of 1ml
The 10mM concentration of sugar alcohol (Dithiothreitol, DTT) Tri(Hydroxymethyl) Amino Methane Hydrochloride buffer solution (Tris-HCl,
PH7.4), and (sonication) is ultrasonically treated, (boiling) is boiled, centrifuges, then precipitation is suspended in 1ml
In PBS, and measure absorbance (synergy 2, microplate reader (VT, the U.S.) under 340nm.In addition, it takes out a part of described super
Solution after sonication measures protein content, as the benchmark of evaluation cell differentiation.And it the results are shown in
In table 9 below.
Table 9
Substances | Differentiation capability (%) in keratinocyte |
Low calcium (0.03mM) solution (negative control group) | 100 |
High calcium (1.2mM) solution (positive controls) | 210 |
Ginsenoside Mc | 285 |
As shown in Table 9 above, it can confirm that the differentiation facilitation effect of keratinocyte is excellent when being handled with ginsenoside Mc
It is different.
[test example 9] skin barrier function recovery effects measure
It is real in order to measure the effect that ginsenoside Mc recovers to generate to the skin barrier function impaired due to skin injury
Following experiments are applied.For the upper arm of 10 adult men and women, the method that (Tape Stripping) is removed with adhesive tape damages skin
Barrier smears the dosage form example 2 prepared according to the composition of table 10 below and compares 2 two groups of dosage form example, uses Vapometer respectively
(dolphin (Delfin), Finland) measures the recovery extent of 1 percutaneous moisture loss amount (TWEL), measures seven days, and carry out daily
Compare.Here comparison dosage form example 2 is the carrier (vehicle) of negative control group.Tested that the results are shown in table 1 below 1
In.Table 11 the result is that the difference of the before processing before barrier injury and after barrier injury is compared as 100% benchmark
As a result.
Table 10
Food ingredient | Dosage form example 2 | Compare dosage form example 2 |
Purified Water | 69 | 70 |
Propylene glycol | 30 | 30 |
Ginsenoside Mc | 1 | - |
Table 11
It was found from from above-mentioned table 11, it can confirm that when the comparison dosage form example 2 for not containing ginsenoside Mc is used to handle, with
The passage of time, percutaneous moisture loss amount gradually increases, on the contrary, when the dosage form example 2 containing ginsenoside Mc is used to handle,
Percutaneous moisture loss amount recovers normal with speed quickly, and barrier injury is restored.
[test example 10] color improvement
It is how general using laser in order to evaluate cosmetic composition according to the present invention to promoting the effect that skin blood cycles
Strangle blood flow imaging instrument (Laser Doppler Perfusion Imager, LDPI;Periscan PIM II, lark prestige
(Perimed) (Stockholm, Sweden)), measure blood circulation degree in skin.Known LDPI is the blood measured in skin
The instrument for cycling, and it is now widely used instrument, is a kind of blood that can not only measure in capillary of skin
Speed and amount, and the very delicate of the flowing in parteriole and veinlet can be measured.
In thermostatic constant wet chamber, after being washed one's face with perfumed soap, adapt to 30 minutes, and initial value is determined using LDPI.First,
It is determined with the initial stage blood flow below the forehead of 30 ice-cold to usually trick LDPI women.Then, experiment pair is made
Blood flow is measured afterwards as using 1 week dosage form example 1 and comparing dosage form example 1, then by the blood flow of measure and the initial stage
The result (skin blood flow variation) that measured value is compared is represented in table 1 below 2.
Table 12
It has been confirmed that cosmetic composition according to the present invention is not with containing ginsenoside Mc from the result of above-mentioned table 12
Comparison dosage form example 1 compare so that skin blood flow dramatically increases, and is promoted by this blood circulation so that complexion obtains
Improve.This finally shows that the cosmetic composition according to the present invention containing ginsenoside Mc can be to effectively transferring skin-nourishing
Simultaneously delay skin aging contributes for ingredient and inhibition.
[test example 11] colour of skin improvement
In order to understand the dosage form example 1 and compare the colour of skin improvement of dosage form example 1,30 test objects is made to use respectively
After (1 times/day of evening smears 1 week altogether), Facial Stage DM-3 (jasmine spy (Moritex), Japan) instrument evaluation is utilized
The colour of skin improves degree.For colour of skin improvement rate, become using the lightness and color measured value of skin and the lightness and color of skin
Change value is judged, and the results are shown in table 1 below 3.Lightness and the higher expression colour of skin of color change value are changed
It is kind.
Table 13
It has been confirmed that not containing the comparison dosage form example 1 of ginsenoside Mc according to the present invention from the result of table 13, do not show
Show that the significant colour of skin improves effect, on the contrary, using containing dosage form examples 1 of the ginsenoside Mc as active ingredient, after use
Compared with the colour of skin is before use, it is greatly improved.
[test example 12] pore refining effect
1. the effect of the pore refining of the biosynthesis by promoting collagen
By ginsenoside Mc according to the present invention to the facilitation effect and Peritoneal fibrosis of the biosynthesis of collagen
β (TGF-β) is compared and is determined.First, by fibroblast with every hole 105The amount of a cell is inoculated in 24 holes
(well) in, and culture is carried out until growing to 90% or so.It is small with serum-free cell culture medium (DMEM) culture 24
When after, respectively using 10ng/ml be dissolved in serum free medium the present invention ginsenoside Mc and TGF-β at
Reason, and in CO2When culture 24 is small in incubator.Their supernatant is taken out, and utilizes procollagen type (I) Enzyme-linked Immunosorbent Assay
Measure (ELISA) kit (procollagen type (I) (procollagen type (I);#MK101, TAKARA (Shiga, Japan)
Come whether observing the increase and decrease of procollagen (procollagen), and the results are shown in table 1 below 4.Non-process group is set to
100 and compared for the synthesis capability of collagen.
Table 14
Substances | Collagen synthesis ability (%) |
Non-process group | 100 |
TGF-β | 183.5 |
Ginsenoside Mc | 195.7 |
It has been confirmed that ginsenoside Mc according to the present invention and positive controls TGF-β phase from the result of above-mentioned table 14
Than showing higher levels of excellent collagen synthesis ability.Therefore, it can confirm that ginsenoside Mc according to the present invention
The pore to broaden is shunk by increasing the collagen growing amount on pore periphery.
2. pore refining effect
In order to understand dosage form example 1 and compare the pore refining effect of dosage form example 1, evaluated as follows.Select 20 pores
The wide men and women's test object of size is divided into two groups by every group 10, and is smearing dosage form example 1 on the face daily according to group and comparing
The nourishing cream of dosage form example 1 is smeared 4 weeks altogether.Judge the effect of pore refining in the following way.Before shooting experiment and after 4 weeks
Photo, and allow expert by visually being evaluated.Its result represents the (opinion rating in table 1 below 5:0- is not received completely
Contracting;5- shrinks very much).
Table 15
Substances | Opinion rating |
Dosage form example 1 | 4 |
Compare dosage form example 1 | 0 |
It was found from from the result of above-mentioned table 15, compare effect of the dosage form example 1 without pore refining, however, dosage form example 1 is shown
The pore refining effect that can with the naked eye confirm, so as to understand that the ginsenoside Mc of the present invention is excellent to the effect of pore refining size
It is different.
[test example 13] sebum secretion inhibition
1. the effect of the inhibition skin hypersecretion by inhibiting 5α-reductase activity
In order to confirm 5α-reductase activity suppression effect, determined in HEK293-5 α R2 cells [14C] testosterone changes into
[14C] dihydrotestosterone (DHT:Dihydrotestosterone ratio).P3x FLAG-CMV-5 α are transfected on HEK293 cells
After R2, and by per hole 2.5 × 105The amount of a cell is inoculated in 24 orifice plates, and cultivated (Park et al., 2003,
JDS.Vol.31, pp.191-98).Change within second day the new culture medium added with zymolyte and inhibitor into.By 0.05 μ Ci
[14C] testosterone (kit (Amersham Pharmacia biotech), Britain) be used as culture substrate.
In order to confirm 5α-reductase activity suppression degree, ginsenoside Mc is added in, and at 37 DEG C, 5%CO2In incubator
Cultivate 2 it is small when.At this point, the group for not adding in ginsenoside Mc is used as negative control group, Finasteride will be added in
(finasteride) group is used as positive controls.Recycle culture medium afterwards, and with 800 μ l ethyl acetate extraction steroids it
Afterwards, the organic solvent layer on top is separated, and after drying, is dissolved to remaining residue, then with 50 μ l ethyl acetate, and in silicon
On plastic film silica gel 60F254 (Silica plastic sheet kieselgel60F254), ethylacetate-hexane is used
(1:1) it is unfolded as solvent.
By plastics sample after being dried in air, shower system has been used in order to measure the amount of isotopeDry sheet plastic and x-ray film are added to bath box togetherIn, 1
The isotopic mass for staying in testosterone and dihydrotestosterone on film is measured after week, then according to following mathematical expressions 5 and 6, is calculated respectively
Conversion ratio and obstruction rate, and the results are shown in table 1 below 6.
Mathematical expression 5
Radiant/total radiant × 100 in conversion ratio (%)=DHT regions
Mathematical expression 6
Conversion ratio × 100 of inhibiting rate (%)=[conversion ratios of conversion ratio-substances of control group]/control group
Table 16
Substances | Conversion ratio (%) | Obstruction rate (%) |
Negative control group | 48.0 | - |
Positive controls | 27.6 | 42.5 |
Ginsenoside Mc | 14.8 | 67 |
It has been confirmed that ginsenoside Mc can effectively inhibit the activity of 5α-reductase from above-mentioned 16 result of table, so as to
Testosterone is blocked to be converted into dihydrotestosterone, and is shown compared with the Finasteride of known inhibition 5α-reductase activity more
Add excellent inhibition.The 5α-reductase makes testosterone be converted into dihydrotestosterone, so as to intracytoplasmic receptor protein knot
It closes and enters in core, so as to activate sebocyte cell and promote to break up, so that the sebum excessive secretion in sebaceous glands.Cause
This, it is thus identified that ginsenoside Mc inhibits the excessive secretion of sebum by effectively inhibiting the activity of 5α-reductase.
2. sebum secretion inhibition
In order to understand the dosage form example 1 and compare the sebum secretion inhibition of dosage form example 1, following evaluation has been carried out.Choosing
Go out 30 men and women's test objects thought more than sebum secretion, smear dosage form example 1 daily in the appointed part of skin on the face and compare
The nourishing cream of dosage form example 1 is smeared 4 weeks altogether.Judgement for sebum minimizing effect, by using sebum tester
(Sebumeter SM810, C+K Electronics Co., Ltd.s (C+K Electronic Co.), Germany) is measured respectively by 2 weeks and 4
Average sebum slip (%) after week, and the results are shown in table 1 below 7.
Table 17
It was found from from the result of above-mentioned table 17, it is of the invention contain ginsenoside Mc as active ingredient dosage form example 1 with
Comparison dosage form example 1 without it is compared, and can effectively inhibit the sebum excessively secreted.
[dosage form example 3 and compare dosage form example 3~4]
It prepares dosage form example 3 according to the ingredient and content (weight %) shown in table 1 below 8 and compares dosage form example 3~4,
It is described as follows.Dosage form example 3 is the substance of mixing ginsenoside Mc, compares dosage form example 3 to improve completely without bag containing acne
The substance of the active ingredient of skin, standard substance of the comparative example 4 as the benchmark for antimicrbial power, which contains is used as Cuo more
The erythromycin (erythromycin) that sore therapeutic agent uses.
Dosage form example 3 and compare dosage form example 3~4 preparation method it is as follows.The ingredient of the A items of table 1 below 8 is completely dissolved,
And in other dissolving tanks, the ingredient of B is completely dissolved, B are added in A afterwards, makes its mixing solubilized.And
Wherein, the ingredient of C is added with the mixed proportion according to described in table 18, and after mixing, is filtered, so as to prepare
This composition.
Table 18
[test example 14] tests the antimicrbial power of acne bacterium
Using each cosmetic composition according to the dosage form example 3 and the composition preparation for comparing dosage form example 3~4, to conduct
Propionibacterium acnes (the ATCC6919 of acne pathogenic strain:Culture medium-brain heart infusion broth culture medium (BHI broth))) into
Row antimicrbial power is tested.
It is as follows to the antimicrbial power test method of acne bacterium.
(1) preparation of test bacteria liquid
Using using propionibacterium acnes be inoculated in brain heart infusion broth culture medium carry out Anaerobic culturel culture solution as
Test bacteria liquid.
(2) preparation of dilute solution
The addition 0.15ml in the brain heart infusion broth culture medium (pH6.8) or LB broth bouillons (pH4.5) of 15ml
The test bacteria liquid, and use using the mixed liquor mixed as dilute solution.
(3) preparation of sample
By dosage form example 3 and the cosmetic composition stoste prepared in dosage form example 3~4 will be compared, made directly as sample
With.
(4) antimicrbial power is tested
1) sample is added in No. 1 row of cell culture tube (96well plate) in 96 holes so that it is matched with initial concentration,
And adding in dilute solution makes total amount be 200 μ l.
2) by the mixed liquor of No. 1 row after mixing, take out the mixed liquor of 100 μ l and be added in No. 2 rows, and mix equal
After even, the mixed liquor of 100 μ l is taken out again and is added in No. 3 rows.Secondary dilution (double is carried out in this way
dilution)。
3) after when quiescent culture 24 is small at 32 DEG C and when 48 is small, judge whether bacterium rises in value with suspension degree, and will
The Cmin for not having the multiplication of bacterium is set to minimum inhibitory concentration (Minimum Inhibitory Concentration, MIC)
Value.It is difficult to judge whether bacterium rises in value if mixed liquor is opaque, confirm by using micro- sem observation.
The antimicrbial power result of the test of acne bacterium is represented in table 1 below 9.For minimum inhibitory concentration, dosage form is converted into
In the concentration of active ingredient that contains and mark.
Table 19
Project | pH | Propionibacterium acnes |
Dosage form example 3 | 5.7 | >52ppm |
Compare dosage form example 3 | 5.7 | Maximum concentration (does not have antimicrbial power) |
Compare dosage form example 4 | 5.7 | >100ppm |
In the result of table 19, in minimum inhibitory concentration, ppm concentration is smaller, it is believed that the substance is to acne bacterium
The effective substance of antimicrbial power, during using dosage form example 3, the comparison dosage form with the erythromycin used as well known acne therapeutic agent
Example 4 is compared, and the ppm concentration shown is significantly low, whereby it was confirmed that the composition containing ginsenoside Mc has test organisms
Superior antimicrbial power.
[test example 15] lipid synthesis (Lipogenesis) inhibits experiment
Using as the 3T3-L1 cells of the fibroblast of mouse (fibroblast cell line), with 1 × 105Carefully
Born of the same parents/hole, which is attached at, fills the DMEM (Dulbecco ' s containing 10% fetal bovine serum (fetal Bovine Serum, FBS)
Modified eagle ' s medium, GIBCO BRL, live technology company) culture medium 6 well culture plate (culture
Plate in).After 2 days, new DMEM (containing 10% FBS) culture medium is re-replaced, and is cultivated 2 days.Then, with containing
There are 1 μ g/ml insulin (insulin), 0.5mM isobutyl methylxanthines (IBMX) and 0.25 μm of dexamethasone
(dexamethasone) DMEM (containing 10% FBS) carries out induction to the cell of the culture, and with 50 μM
Then ginsenoside Mc and caffeine processing, after 2 days, re-replace into the DMEM comprising insulin, and cultivate 5 days.5
After it, normal incubation medium (DMEM contains 10% FBS) is re-replaced into, and the cell is observed and is cultivated to institute
It states cell and changes lipoblast from form.
In order to evaluate the effect of ginsenoside Mc is to inhibiting Fat Accumulation in adipocyte, complete what is broken up using described
3T3-L1 adipocytes are implemented the Sudan three and are dyed (S4136, Sigma-Aldrich).At normal temperatures, in phosphate buffer
In, after 4% paraformaldehyde (pH7.2) fixed fat cell, washed with phosphate buffer, then, with the Sudan three into
Photo is shot after row dyeing, and passes through naked eyes and is compared.It will be not added with substances or compare substance and culture medium is used only
Group use as a control group, for other comparative groups, handled with 50 μM of caffeines.Fat Accumulation inhibition level is to pass through
The degree of dyeing is divided into +++, ++ ,+,-, so as to assign grade, at this point, closer +++, represent that dye levels are bigger.It is tied
Fruit is represented in table 2 below 0.
Table 20
As shown in above-mentioned table 20, the ginsenoside Mc used in the present invention can confirm that, not only accumulation in adipocyte
Fat mass it is few, and compared with as the caffeine of well known lipid synthesis inhibiting substances, also with excellent lipid synthesis
Inhibition.Therefore, sebum is reduced by inhibiting lipid synthesis, so as to inhibit the generation of acne.
[test example 16] acne improves and sebum secretion reduces and stimulate the experiment whetheing there is
Using 30 people with acne as subjects, it is divided into three groups, and the examination to corresponding to each group with every group 10
Object is tested using with the dosage form example 3 and comparing dosage form example 3~4 cosmetic composition for preparing 1 month.Improve for acne
Standard, is set as 1 point to 5 points, and mark 1 divides for " not having ", and 3 points are " common ", and 5 points are " very good ".For experimental result, with
The average mark of 10 is marked in table 2 below 1.
Period is eliminated for acne, to recognize the number of days of elimination as benchmark, for acne recurrence, to have after 1 month
Without recurrence as benchmark.Reduction for sebum secretion is set as 1 point to 5 points, and is marked as 1 point as " not having ", and 3 points are " general
It is logical ", 5 points are " very good ".For experimental result, marked with the average mark of 10 in table 2 below 1.With (showing stimulates instead
The number answered)/(overall test number) judge the presence or absence of skin irritatin.
Table 21
As shown in above-mentioned table 21, it is known that the dosage form example 3 compared with of dosage form example 3 is compared, acne does not recur, and whole
Acne, which is improved, on body has excellent effect.In addition, during using comparison dosage form example 4 containing antimicrbial power standard substance, although
It is strong to the stimulation of skin when showing acne improvement, but using the substance, therefore be not suitable for long-time service, however,
Composition according to the present invention does not stimulate but, thus it is shown that also being adapted for using for a long time.
[test example 17] inflammation improvement-interleukin 8 (IL-8) generation inhibition
Before one day tested, by Keratoderma epithelial cell (Normal human skin keratinocyte,
NHEK buys place:Lonza), with 5 × 104Cells/well is inoculated in 96 orifice plates, then at 37 DEG C, 5%CO2Incubator
(incubator) when culture 24 is small in.24 it is small when after, clean cell 2 times with phosphate buffer, and be replaced with serum-free angling
Cell basal culture medium (serum free keratinocyte basement media (KBM)).In each hole, use respectively
The ginsenoside Mc processing of 5ppm, 25ppm and 50ppm concentration, and react 30 minutes after, use staphylococcus aureus respectively
Peptide glycan (PGSA) (10 μ g/ml), aureus peptide glycan (50 μ g/ml) and aureus peptide glycan (50 μ
G/ml)+lipopolysaccharides (1 μ g/ml) processing.Wherein, aureus peptide glycan (PGSA:peptidoglycan from
S.aureus it is the cell of Gram-positive (+) bacterium) as the peptide glycan (peptidoglycan) extracted from staphylococcus
The main constituents of wall, and the cell membrane component of known bacterium can induce inflammation.According to the report, especially staphylococcus, allergy
Property dermatitis patients 90% or so because the bacterium generate superinfection.Known lipopolysaccharides (LPS:Lypopolysaccaride it is) leather
The main constituents of the cell membrane of Lan Shi feminine gender (-) bacterium, and be the main reason for inflammation induces.
At 37 DEG C, 5%CO2After when culture 24 is small in incubator, takes out culture solution and carry out to interleukin 8
The enzyme-linked immunosorbent assay (ELISA) of (Interleukin-8, IL-8), and the results are shown in table 2 below 2.For
ELISA make use of the experimental method of preparation company (BD science).
Table 22
Classification | The secretion (pg/ml) of interleukin 8 |
Without processing control group (control) | 935.12 |
PGSA(10μg/ml) | 4812.60 |
PGSA(50μg/ml) | 5895.08 |
PGSA(50μg/ml)+LPS(1μg/ml) | 6814.91 |
Ginsenoside Mc (5ppm) | 1573.32 |
Ginsenoside Mc (25ppm) | 1203.54 |
Ginsenoside Mc (50ppm) | 1001.23 |
It has been confirmed that ginsenoside Mc can be substantially reduced and inhibited due to PGSA and lipopolysaccharides LPS from above-mentioned table 22
The secretion of increased interleukin 8.As a result it will be appreciated that the present invention Dermatologic preparation composition can substantially reduce because
The secretion of PGSA and LPS and increased interleukin 8, so as to provide excellent anti-inflammatory effect.
[test example 18] itch alleviates evaluation
Before one day tested, by keratinocyte (cell line title:HaCaT buys place:US mode culture
Object preservation institute (ATCC)), with 4 × 104Cells/well is inoculated in 96 orifice plates, then at 37 DEG C, 5%CO224 are cultivated in incubator
Hour.24 it is small when after, it is clear with balanced salt solution (Hanks ' Balanced Salt solution, HBSS) buffer solution of hanks
After washing (washing) 96 orifice plate 2 times, by reaction buffer (2 μM of Fluo-4-AM, 20% pluronic acid (pluronic
Acid), 2.5mM probenecid (probenecid)) it is put into cell.At 37 DEG C, 5%CO2It is reacted 30 minutes in incubator, and
After reacting 30 minutes at normal temperatures, with HBSS buffer solution for cleaning 2 times, and (weighed with 0.05%, 0.1%, 0.5% and 1.0% concentration
Amount %) ginsenoside Mc handle cell.
Reaction after ten minutes, is carried out with the trypsase (trypsin) of 2U/ml or 5 μM of PAR-2 active peptides (SLIGKV)
Processing, and measure intracellular Ca2+Concentration changes 80 seconds.For intracellular Ca2+The measure of concentration variation, make use of microplate reader 3
(FlexStation3:Molecular device (Molecular Device), the U.S.).With the trypsase of ginsenoside Mc and 2U/ml
(trypsin) or after 5 μM of PAR-2 active peptides (SLIGKV) processing, the bending (flex) of 80 seconds is measured, and be obtained
After the minimum value of value and the difference of maximum, by the value with using 2U/ml trypsase or 5 μM of PAR-2 active peptides
(SLIGKV) difference of minimum value and maximum when handling is compared, and intracellular inhibiting rate (%) table is poured in calcium ion
Show in table 2 below 3.
Table 23
It is recognised that the calcium ion caused by trypsase or PAR-2 active peptides (SLIGKV) is to thin from above-mentioned table 23
Intracellular pours in, and is reduced with the processing of ginsenoside Mc, and can confirm that with the concentration for improving ginsenoside Mc, calcium
Ion is substantially reduced to intracellular pouring in.
Therefore, the Dermatologic preparation composition of the ginsenoside Mc containing the present invention, by effectively inhibiting to induce itch
PAR-2 activity, so as to provide excellent antipruritic effect.
[dosage form example 4 and compare dosage form example 5]
Shampoo is prepared with the composition of table 2 below 4.Specifically, surfactant and glycol distearate are added
It is added in Purified Water, and after being heated to 80 DEG C and making its uniform dissolution, is cooled to 40 DEG C gradually under stiring, also, described
After active ingredient according to the present invention and preservative, viscosity modifier, fragrance and hair conditioner are added in mixture and is mixed,
It is cooled to room temperature under stiring, so as to prepare shampoo.
Table 24
Ingredient | Dosage form example 4 | Compare dosage form example 5 |
Ammonium lauryl sulfate | 10 | 10 |
Polyoxyethylene lauryl base ammonium sulfate | 5 | 5 |
Cocoamidopropyl betaine | 2 | 2 |
Glycol distearate | 1.5 | 1.5 |
Cocomonoethanolamide | 0.8 | 0.8 |
Ginsenoside Mc | 5.0 | - |
Polyquaternium-10 | 0.2 | 0.2 |
Blueness 1 | 0.0002 | 0.0002 |
Yellow 4 | 0.0001 | 0.0001 |
Methyl p-hydroxybenzoate | 0.1 | 0.1 |
Fragrance | 0.8 | 0.8 |
Citric acid | 0.1 | 0.1 |
Dimethicone | 1.0 | 1.0 |
Water | To 100 | To 100 |
[test example 19] dandruff minimizing effect is tested
The more male of 19 to 35 years old of 24 dandruffs is selected, is divided into two groups with every group 12, and divides with the following methods
Not using dosage form example 4 and after comparing the shampoo 1 month of dosage form example 5, dandruff slip is measured.
Before on-test, hair usually is cleaned with conventional shampoo, the dandruff for then accumulating two days after acquisition hair washing,
And by the weight of the dandruff of acquisition with respectively with dosage form example 4 and compared with dosage form example 5 shampoo washed every two days a hair and
The weight for the dandruff for accumulating two days after the test is compared and evaluates.At this point, the scalp crumb vacuum suck by accumulation
Device is directly gathered from scalp, and dandruff slip is obtained according to following mathematical expressions 7, and the results are shown in following tables
In 25.
Mathematical expression 7
Dandruff slip (%)=(dandruff weight of the dandruff weight (mg) after-one month before on-test
(mg)) the dandruff weight (mg) × 100 before/on-test
Table 25
It is recognised that the dosage form example 4 containing ginsenoside Mc shows that excellent dandruff prevents from imitating from above-mentioned table 26
Fruit.
[test example 20] pruritus of scalp prevents the experiment of effect
Selected 24 than the more serious men and women of 25 years old to 45 years old for feeling itching of the scalp, are divided into two groups with every group 12,
And, pass through following evaluation criteria pair with each dosage form example 4 of frequency usage once three days and the shampoo for comparing dosage form example 5 after two weeks
Pruritus of scalp prevents effect from being evaluated, and the results are shown in table 2 below 6.
[evaluation criteria]
It is -5 points very excellent
Excellent -4 points
Generally -3 points
Bad -2 points
It is -1 point very bad
Table 26
Classification | Dosage form example 4 | Compare dosage form example 5 |
The removal effect of pruritus of scalp | 4.2 | 2.3 |
It is recognised that the dosage form example 4 containing ginsenoside Mc prevents from showing to pruritus of scalp from above-mentioned table 26
Superior effect.
[test example 21] potassium ion channel activity increases effect assessment
Minoxidil as alopeciaing therapeutic agent is known as potential mitochondria K ~+Channel Opener (KATP
Channel opener), it is the representative drugs used in the treatment of androgenetic alopecia.In order to evaluate this minoxidil
Mechanism, used following test method(s)s.The test method(s) is the prevention K in the fibroblast using composition scalp coriumATPIt is logical
The orinase (SIGMA AIDRICH, T0891) in road is handled, and so as to inhibit the multiplication of cell, and is again turned on potassium
Ion channel and recover cell Proliferation.
In order to evaluate the K as this compositionATPThe function of channel opener, present invention uses as fibroblast
Mouse embryonic fibroblasts system (Mouse embryonic fibroblast the cell line, NIH3T3 of system:).This cell
It is for 3T3 schemes (protocol), to separated into fiber from NIH Swiss mouse embryos (Swiss mouse embryo)
Cell line carries out cell line obtained from nature immortalization.The cell line, containing 10%FBS DMEM (Gibco BRL,
Gaithersburg, MD, the U.S.) in, maintaining 5%CO2, when culture 24 is small in 37 DEG C of incubator.NIH3T3 is inoculated in 96 holes
In plate, and when culture 24 is small in 37 DEG C of incubator after, handled with the orinase of 2.5mM, and at 10 minutes
Afterwards, serve as 10 μM of minoxidil of positive controls and the ginsenoside Mc of 2.5ppm, 5ppm and 10ppm concentration into
Row processing, and after drug-treated when 48 is small after, WST-1 kits (Roche (Roche)) is used to measure cell Proliferation energy
Power.As a result represent in table 2 below 7.
Table 27
Classification | Ability of cell proliferation (%) |
Without processing control group (control) | 100 |
Minoxidil | 132 |
Ginsenoside Mc (2.5ppm) | 115 |
Ginsenoside Mc (5ppm) | 123 |
Ginsenoside Mc (10ppm) | 130 |
From above-mentioned table 27 it is recognised that when being handled with ginsenoside Mc, fibroblastic multiplication is restored, and
Ability of cell proliferation increases dependent on the concentration of the ginsenoside Mc of processing, and can confirm that with 10ppm ginsenosides Mc
During processing, cell Proliferation is restored to level when being handled with minoxidil.
The melanin generation facilitation effect experiment of [test example 22] ginsenoside Mc
The penicillin of the fetal bovine serum of addition 5%, 100IU in serum-free cell freezing media (RPMI culture mediums)
In the culture medium of G and 0.2 μM of terephthalic acid (TPA) (TPA), by melanocyte, with 50,000 cells/wells, 24 orifice plates are inoculated in
In.Second day, to the cell of inoculation, by the use of at the ginsenoside Mc as substances of the ultimate density of 10ppm or 50ppm
Reason.It, will be at 100 μM of isobutyl methylxanthine (IBMX) using the group handled by the use of 0.1% DMSO as negative control group
The group of reason cultivates above-mentioned each group three days as positive controls at a temperature of 37 DEG C.After culture, phosphate buffer is used
(PBS) cleaning orifice, and after adding in the 1N NaOH of 100 μ l in every hole, dissolve the melanin in cell.Utilize tablet culture
Analyzer (microplate reader) measures absorbance (synergistic effect 2, the enzyme mark of dissolved melanin under 405nm
Instrument (VT, the U.S.).Result of the melanin generation facilitation effect of ginsenoside Mc compared with control group is represented following
In table 28.
Table 28
Sample | B16 cell amount (%) |
DMSO (0.1%) | 100 |
IBMX(100μM) | 120 |
Ginsenoside Mc (10ppm) | 112 |
Ginsenoside Mc (50ppm) | 121 |
It is recognised that ginsenoside Mc promotes the B16 cell of melanocyte, so as to increase black from above-mentioned table 28
The generation of element, therefore can show that excellent melanin generation facilitation effect.
Promotion transcription factors (MITF) and tyrosinase expression of [test example 23] the ginsenoside Mc in melanocyte
Effect
Using 501mel cell lines, with 500,000 cells/wells, it is inoculated in 6 orifice plates, and in each hole, with 0.1%
Dimethyl sulfoxide (DMSO) (DMSO) processing conduct negative control group, by the use of 100 μM of IBMX processing as positive controls and
By the use of the life saponin(e Mc of 10ppm handle as experimental group, and cultivated at a temperature of 37 DEG C 24 it is small when, 48 it is small when and 72 it is small when
Afterwards, protein is obtained.For the protein so obtained, western blot (Western is carried out using MITF and tyrosinase
Blot) method is tested.Protein Extraction and western blot are implemented by the usually used standard method of those skilled in the art.
After implementing western blot, the negative control group in its result is set to 100, and is represented compared with the value in table 2 below 9
In.
Table 29
As shown in above-mentioned table 29, it can confirm that ginsenoside Mc improves MITF and tyrosinase protein in melanocyte
The expression of matter.
The antimicrbial power evaluation of [test example 24] ginsenoside Mc
In order to evaluate the antimicrbial power of ginsenoside Mc, antibacterial experiment is implemented.Specific test method is as described below.
Staphylococcus aureus (Staphylococcus aureus), the Escherichia coli used in experiment
(Escherichia coli) and pseudomonas aeruginosa (Pseudomonas aeruginosa) are in trypticase soya broth
Culture in culture medium (Tryptic Soy Broth);Candida albicans (Candida albicans) and aspergillus niger
(Aspergillus niger) is the culture in Sabouraud dextrose broth bouillon (Sabouraud Dextrose Broth).
By culture solution in each culture medium with the dilution that 1/100 (albicans strain is using 1/10) is diluted as test organisms
Liquid uses.For aspergillus niger, 2 × 10 will be prepared into8The spore suspension of cfu/ml is as test bacteria liquid.
The mixed liquor that the test bacteria liquid that 0.15ml is added in each culture medium of 15ml is mixed is as dilute solution
To use.
In No. 1 row of 96 orifice plate, the ginsenoside Mc of 10ppm is separately added into the amount of every 16 μ l of hole, and is separately added into
The dilute solution of 184 μ l.The dilute solution of 100 μ l is separately added into other holes.The mixed liquor of No. 1 row is uniformly mixed
Afterwards, the mixed liquor for taking out 100 μ l is added in No. 2 rows, and after mixing, the mixed liquor for taking out 100 μ l again is added to No. 3
In row.Doubling dilution has been carried out in this way.
Staphylococcus aureus, Escherichia coli and pseudomonas aeruginosa are cultivated in 32 DEG C of thermostat;Candida albicans
Bacterium and aspergillus niger are cultivated in 25 DEG C of thermostat.
48 it is small when after, with suspensibility and microscope come whether confirming the increment of bacterium, so as to determine minimum inhibitory concentration (MIC)
Value, and the results are shown in Table 3 below 0.
Table 30
As shown in above-mentioned table 30, it can confirm that ginsenoside Mc shows antimicrbial power to a variety of bacterial strains, and pass through this
It can predict that ginsenoside Mc can work in composition as natural antiseptic agent or antiseptic a bit.
Claims (14)
1. the cosmetic combinations of improvement acne are being prepared as the Dermatologic preparation composition of active ingredient comprising ginsenoside Mc
Application in object.
2. applications of the ginsenoside Mc as unique active ingredient in the cosmetic composition for improving acne is prepared.
3. the cosmetics of offer antibacterial action are being prepared as the Dermatologic preparation composition of active ingredient comprising ginsenoside Mc
Application in composition.
4. applications of the ginsenoside Mc as unique active ingredient in the cosmetic composition for providing antibacterial action is prepared.
5. the cosmetics of offer anti-inflammatory effect are being prepared as the Dermatologic preparation composition of active ingredient comprising ginsenoside Mc
Application in composition.
6. applications of the ginsenoside Mc as unique active ingredient in the cosmetic composition for providing anti-inflammatory effect is prepared.
7. the makeup of improvement allergic skin is being prepared as the Dermatologic preparation composition of active ingredient comprising ginsenoside Mc
Application in product composition.
8. applications of the ginsenoside Mc as unique active ingredient in the cosmetic composition for improving allergic skin is prepared.
9. the cosmetic combinations of pore refining are being prepared as the Dermatologic preparation composition of active ingredient comprising ginsenoside Mc
Application in object.
10. applications of the ginsenoside Mc as unique active ingredient in the cosmetic composition for preparing pore refining.
11. the cosmetic combinations of adjusting sebum are being prepared as the Dermatologic preparation composition of active ingredient comprising ginsenoside Mc
Application in object.
12. applications of the ginsenoside Mc as unique active ingredient in the cosmetic composition for adjusting sebum is prepared.
13. the change of offer anti-dandruff effect is being prepared as the Dermatologic preparation composition of active ingredient comprising ginsenoside Mc
Application in cosmetic compositions.
14. ginsenoside Mc answering in the cosmetic composition that anti-dandruff effect is provided is prepared as unique active ingredient
With.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130045117A KR102048709B1 (en) | 2013-04-24 | 2013-04-24 | External composition for skin containing Ginsenoside Mc |
KR10-2013-0045117 | 2013-04-24 | ||
CN201480029499.7A CN105555278B (en) | 2013-04-24 | 2014-04-24 | Dermatologic preparation composition containing ginsenoside Mc |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480029499.7A Division CN105555278B (en) | 2013-04-24 | 2014-04-24 | Dermatologic preparation composition containing ginsenoside Mc |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108066170A true CN108066170A (en) | 2018-05-25 |
Family
ID=51792146
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711172456.6A Pending CN108066170A (en) | 2013-04-24 | 2014-04-24 | Dermatologic preparation composition containing ginsenoside Mc |
CN201711171123.1A Active CN107970251B (en) | 2013-04-24 | 2014-04-24 | Skin external composition containing ginsenoside Mc |
CN201480029499.7A Active CN105555278B (en) | 2013-04-24 | 2014-04-24 | Dermatologic preparation composition containing ginsenoside Mc |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711171123.1A Active CN107970251B (en) | 2013-04-24 | 2014-04-24 | Skin external composition containing ginsenoside Mc |
CN201480029499.7A Active CN105555278B (en) | 2013-04-24 | 2014-04-24 | Dermatologic preparation composition containing ginsenoside Mc |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR102048709B1 (en) |
CN (3) | CN108066170A (en) |
HK (1) | HK1218077A1 (en) |
TW (2) | TWI653042B (en) |
WO (1) | WO2014175675A1 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1182433A (en) * | 1996-02-22 | 1998-05-20 | 株式会社一和 | Metabolites of ginseng saponins by human intestinal bacteria and its preparation for anticancer |
US5925537A (en) * | 1996-11-29 | 1999-07-20 | Il Hwa Co., Ltd. | Process for the preparation of metabolites of Ginseng saponins |
JP2005325063A (en) * | 2004-05-14 | 2005-11-24 | Asahi Kasei Chemicals Corp | Cosmetic |
KR20060122577A (en) * | 2005-05-27 | 2006-11-30 | 주식회사 비티진 | A preparation method of ginsenoside mc and mc-1 |
KR20070115458A (en) * | 2006-06-02 | 2007-12-06 | 청강문화산업대학 산학협력단 | Melanin biosynthesis inhibitors which using of ginsenosides |
CN101443025A (en) * | 2006-05-17 | 2009-05-27 | 拜耳消费者保健股份公司 | Use of ginsenosides and extracts containing them |
WO2012148249A2 (en) * | 2011-04-29 | 2012-11-01 | 한국생명공학연구원 | Lactic acid bacteria-derived glycoside hydrolase and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2695561B1 (en) * | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Cosmetic or dermatological composition containing at least one ginsenoside-type saponin, and its applications, in particular for hair care. |
CN1230553C (en) * | 2002-12-13 | 2005-12-07 | 中国科学院大连化学物理研究所 | Anti-tumour ginseng saponin preparing method |
KR101079293B1 (en) * | 2009-03-27 | 2011-11-04 | 건국대학교 산학협력단 | Method of rare ginsenosides production using thermostable beta-glycosidase |
KR101221417B1 (en) * | 2010-07-08 | 2013-01-11 | 세명대학교 산학협력단 | Composition including ginseng berry extract for promoting hair growth |
-
2013
- 2013-04-24 KR KR1020130045117A patent/KR102048709B1/en active IP Right Grant
-
2014
- 2014-04-24 TW TW103114699A patent/TWI653042B/en active
- 2014-04-24 CN CN201711172456.6A patent/CN108066170A/en active Pending
- 2014-04-24 CN CN201711171123.1A patent/CN107970251B/en active Active
- 2014-04-24 WO PCT/KR2014/003590 patent/WO2014175675A1/en active Application Filing
- 2014-04-24 TW TW107121335A patent/TWI652061B/en active
- 2014-04-24 CN CN201480029499.7A patent/CN105555278B/en active Active
-
2016
- 2016-05-31 HK HK16106181.8A patent/HK1218077A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1182433A (en) * | 1996-02-22 | 1998-05-20 | 株式会社一和 | Metabolites of ginseng saponins by human intestinal bacteria and its preparation for anticancer |
US5925537A (en) * | 1996-11-29 | 1999-07-20 | Il Hwa Co., Ltd. | Process for the preparation of metabolites of Ginseng saponins |
JP2005325063A (en) * | 2004-05-14 | 2005-11-24 | Asahi Kasei Chemicals Corp | Cosmetic |
KR20060122577A (en) * | 2005-05-27 | 2006-11-30 | 주식회사 비티진 | A preparation method of ginsenoside mc and mc-1 |
CN101443025A (en) * | 2006-05-17 | 2009-05-27 | 拜耳消费者保健股份公司 | Use of ginsenosides and extracts containing them |
KR20070115458A (en) * | 2006-06-02 | 2007-12-06 | 청강문화산업대학 산학협력단 | Melanin biosynthesis inhibitors which using of ginsenosides |
WO2012148249A2 (en) * | 2011-04-29 | 2012-11-01 | 한국생명공학연구원 | Lactic acid bacteria-derived glycoside hydrolase and uses thereof |
Non-Patent Citations (1)
Title |
---|
国家中医药管理局专业技术资格考试专家委员会编写: "《全国临床中医学中西医结合医学中药学中医护理学专业技术资格考试大纲与指南 中药学 中级 第2版》", 31 March 2011, 中国中医药出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN107970251B (en) | 2020-07-10 |
CN105555278B (en) | 2018-02-23 |
KR20140126890A (en) | 2014-11-03 |
KR102048709B1 (en) | 2019-11-27 |
WO2014175675A1 (en) | 2014-10-30 |
TW201832769A (en) | 2018-09-16 |
TW201521736A (en) | 2015-06-16 |
TWI653042B (en) | 2019-03-11 |
CN107970251A (en) | 2018-05-01 |
HK1218077A1 (en) | 2017-02-03 |
CN105555278A (en) | 2016-05-04 |
TWI652061B (en) | 2019-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107693527B (en) | Skin external composition containing ginsenoside F2 from hydroponic ginseng | |
KR101928797B1 (en) | Composition of skin external application containing compound K | |
CN105283189A (en) | Topical composition for skin containing gincenoside RG3 | |
US10022415B2 (en) | External composition for skin containing an enzyme-treated saponin fraction derived from the root of Camellia sinensis | |
CN105246489B (en) | Dermatologic preparation composition containing ginsenoside RF | |
CN105188711B (en) | Dermatologic preparation composition containing ginsenoside RH4 | |
CN105555278B (en) | Dermatologic preparation composition containing ginsenoside Mc | |
KR101939112B1 (en) | Composition of skin external application containing ginsenoside F1 | |
KR101939111B1 (en) | Composition of skin external application containing ginsenoside F2 | |
KR101909533B1 (en) | Composition of skin external application containing ginsenoside F1 | |
CN105163742B (en) | Dermatologic preparation composition containing ginsenoside Y | |
US11684564B2 (en) | Cosmetic composition for improving skin containing taraxacum coreanum phytoplacenta culture extract that has moisturizing and soothing effects for extremely dry skin such as atopic dermatitis, and skin barrier strengthening effect | |
KR101939113B1 (en) | Composition of skin external application containing ginsenoside F2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180525 |